The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease - Sevigny, Jeff; Chiao, Ping; Bussière, Thierry; Weinreb, Paul H.; Williams, Leslie; Maier, Marcel; Dunstan, Robert; Salloway, Stephen; Chen, Tianle; Ling, Yan; O’Gorman, John; Qian, Fang; et al. (Nature (London), 2016)
Keywords: 692/308/153; 692/699/375/132; Aged; Aged, 80 and over; Alzheimer Disease - drug therapy; Alzheimer Disease - metabolism; Alzheimer Disease - pathology; Alzheimer Disease - psychology; Amyloid - drug effects; Amyloid - metabolism; Amyloid beta-Peptides - antagonists & inhibitors; Amyloid beta-Peptides - chemistry; Amyloid beta-Peptides - metabolism; Animals; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacokinetics; Antibodies, Monoclonal, Humanized - therapeutic use; Brain - drug effects; Brain - metabolism; Clinical Trials, Phase III as Topic; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humanities and Social Sciences; Humans; Male; Mice; Mice, Transgenic; Middle Aged; Models, Biological; multidisciplinary; Plaque, Amyloid - drug therapy; Plaque, Amyloid - metabolism; Plaque, Amyloid - pathology; Protein Aggregation, Pathological - drug therapy; Science; Solubility